The Ubiquitin-Proteasome Pathway and Pathogenesis of Human Diseases
- 1 February 1999
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 50 (1) , 57-74
- https://doi.org/10.1146/annurev.med.50.1.57
Abstract
The ubiquitin-proteasome pathway plays a pivotal role in the degradation of short-lived and regulatory proteins important in a variety of basic cellular processes, including regulation of the cell cycle, modulation of cell surface receptors and ion channels, and antigen presentation. The pathway involves an enzymatic cascade through which multiple ubiquitin molecules are covalently attached to the protein substrate, which is then degraded by the 26S proteasome complex. The pathway has been implicated in several forms of malignancy, in the pathogenesis of several genetic diseases (including cystic fibrosis, Angelman's syndroome, and Liddle syndrome), in immune surveillance/viral pathogenesis, and in the pathology of muscle wasting. The molecular mechanisms that underlie these processes are being unraveled at present.Keywords
This publication has 80 references indexed in Scilit:
- Signal transduction through NF-κBImmunology Today, 1998
- Ubiquitin Lys63 is involved in ubiquitination of a yeast plasma membrane proteinThe EMBO Journal, 1997
- Structure of 20S proteasome from yeast at 2.4Å resolutionNature, 1997
- Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle.Journal of Clinical Investigation, 1997
- UBE3A/E6-AP mutations cause Angelman syndromeNature Genetics, 1997
- Rapid Degradation of the G 1 Cyclin Cln2 Induced by CDK-Dependent PhosphorylationScience, 1996
- Metabolism of the polyubiquitin degradation signal: structure, mechanism, and role of isopeptidase TBiochemistry, 1995
- Protein ubiquitination involving an E1–E2–E3 enzyme ubiquitin thioester cascadeNature, 1995
- Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle.Journal of Clinical Investigation, 1994
- The N-end rule is mediated by the UBC2(RAD6) ubiquitin-conjugating enzyme.Proceedings of the National Academy of Sciences, 1991